Nov 18, 2025 04:15PM
Oct 7, 2025 08:30AM
Oct 2, 2025 08:30AM
Oct 1, 2025 09:21AM
Sep 11, 2025 08:00AM
Jul 9, 2025 08:00AM
Jul 9, 2025 08:00AM Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase
Nov 10, 2023 07:01AM
Nov 1, 2023 07:01AM
Oct 23, 2023 07:01AM
Oct 11, 2023 07:01AM
Oct 5, 2023 07:01AM
Sep 29, 2023 07:01AM
Jul 6, 2023 07:00AM KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
Jun 8, 2023 07:00AM
May 25, 2023 07:01AM
Apr 14, 2023 07:02AM
Apr 14, 2023 07:01AM
Apr 4, 2023 07:00AM
Dec 15, 2022 07:01AM
Dec 12, 2022 07:01AM KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
Dec 1, 2022 07:01AM
Nov 9, 2022 07:00AM
Oct 27, 2022 07:00AM
Oct 6, 2022 08:00AM
Sep 9, 2022 08:00AM
Sep 8, 2022 08:30AM
Aug 5, 2022 08:40AM KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
Jul 12, 2022 08:15AM
Jul 6, 2022 07:00AM
Jun 17, 2022 08:00AM
Jun 13, 2022 07:00AM
Jun 7, 2022 07:00AM
Jun 3, 2022 07:00AM
May 31, 2022 07:00AM GBM AGILE OPENS TO PAXALISIB IN EUROPE
May 23, 2022 08:30AM
May 17, 2022 08:00AM
Apr 29, 2022 11:00AM
Apr 8, 2022 08:30AM
Apr 8, 2022 08:00AM
Mar 21, 2022 08:00AM
Feb 28, 2022 08:00AM PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
Feb 7, 2022 08:00AM
Jan 25, 2022 08:00AM
Jan 7, 2022 08:00AM
Dec 13, 2021 11:00AM
Dec 4, 2021 08:00AM
Nov 29, 2021 08:00AM
Nov 15, 2021 11:00AM Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer
Nov 11, 2021 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All